The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. RESULTS: Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS: Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inter- and intra-driver heterogeneity are also evident following treatment with inhibitors of the immune checkpoint molecules PD-1 or PD-L1, with only ~20% of unselected NSCLC patients deriving durable clinical benefit38–43.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [39]
In the citing paper
“other features such as TMB appear to also be associated with clinical benefit to PD-1 / PD-L1 antibodies”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I. O., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 758
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Shafique, M. R., & Tanvetyanon, T. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1571036 · Cited by 28
Guo, X., Li, W., Hu, J., Zhu, E. C., & Su, Q. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02903-2 · Cited by 28
García, J., Bañobre, J. R., Afonso-Afonso, F. J., Amenedo, M., Manrique, M. C. A., Campos, B., Casal‐Rubio, J., Núñez, N. F., Pérez, J. L. F., Lázaro-Quintela, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072093 · Cited by 28
Xia, W.-Y., Feng, W., Zhang, C., Shen, Y., Zhang, Q., Yu, W. J., Cai, X., & Fu, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-827 · Cited by 30
Goruganthu, M., Shanker, A., Dikov, M. M., & Carbone, D. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01958 · Cited by 29
Self-citationDong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 29
Zhang, H., Liu, P., Zhang, Y., Han, L., Hu, Z., Cai, Z., & Cai, J. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13088 · Cited by 28
Sacdalan, D. B., & Lucero, J. A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s278089 · Cited by 28
Spagnolo, F., Boutros, A., Cecchi, F., Croce, E., Tanda, E. T., & Queirolo, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08165-0 · Cited by 31
Ikarashi, D., Okimoto, T., Shukuya, T., Onagi, H., Hayashi, T., Sinicropi-Yao, S. L., Amann, J. M., Nakatsura, T., Kitano, S., & Carbone, D. P. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100230 · Cited by 28
Self-citationMadala, S., Rasul, R., Singla, K., Sison, C. P., Seetharamu, N., & Castellanos, M. R. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.03.010 · Cited by 29
Lin, E. P.-Y., Hsu, C., Berry, L. D., Bunn, P. A., & Shyr, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.27211 · Cited by 29
Huang, Y., Xie, W.-J., Fan, H., & Du, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00972 · Cited by 29
Sui, J.-D., Wang, Y., Wan, Y., & Wu, Y. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s167077 · Cited by 27
Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
Tsukamoto, J. S., Monteiro, M. R., do Vale, S. K. M., Lemos, C., Scarpelli, T., Carvalho, L. L. M., Pezzutti, D., & Moreira, R. B. (2018) · Case Reports in Oncology · doi:10.1159/000492463 · Cited by 27
The role of circulating free DNA in the management of NSCLC
Abate, R. E., Pasquale, R., Fenizia, F., Rachiglio, A. M., Roma, C., Bergantino, F., Forgione, L., Lambiase, M., Sacco, A., Piccirillo, M. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1548938 · Cited by 26
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Raphael, J., Batra, A., Boldt, G., Shah, P. S., Blanchette, P., Rodrigues, G., & Vincent, M. D. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.004 · Cited by 27
Liang, J., Li, M., Sui, Q., Hu, Z., Bian, Y., Huang, Y., Zhan, C., Jiang, W., Wang, Q., & Tan, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-192 · Cited by 27
Li, X., Huang, C., Xie, X., Wu, Z., Tian, X., Wu, Y., Du, X., & Shi, L. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13309 · Cited by 28
Kartolo, A., Feilotter, H. E., Hopman, W. M., Fung, A. S., & Robinson, A. G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100330 · Cited by 27
Majem, M., Cobo, M., Isla, D., Márquez-Medina, D., Rodríguez‐Abreu, D., Casal‐Rubio, J., Morán, T., Bernabé, R., Pérez-Parente, D., Gracia, P. R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071365 · Cited by 28
Self-citationYu, W., Ye, F., Yuan, X., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F.-H., Li, J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08590-1 · Cited by 27
Asgari, A., Lesyk, G. M., Poitras, E., Govindasamy, N. P., Terry, K., To, R. K., Back, V., Rudzinski, J. K., Lewis, J. D., & Jurasz, P. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15478 · Cited by 27
Murugesan, K., Sharaf, R., Montesion, M., Moore, J. A., Pao, J. J., Pavlick, D. C., Frampton, G. M., Upadhyay, V. A., Alexander, B. M., Miller, V. A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00397 · Cited by 27
Peris, B. H., Garde, J., García-Sánchez, J., Piera, N., Llombart‐Cussac, A., & Fernández-Murga, M. L. (2021) · Cancers · doi:10.3390/cancers13174280 · Cited by 27
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Wang, C., Li, J., Zhang, Q., Wu, J., Xiao, Y., Song, L., Gong, H., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08662-2 · Cited by 27
Gu, J., Shi, L., Jiang, X., Wen, J., Zheng, X., Hu, C., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03140-5 · Cited by 27
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 29
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 28
Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Corke, L., Li, J. J. N., Leighl, N. B., & Eng, L. (2022) · Current Oncology · doi:10.3390/curroncol29090492 · Cited by 27
Lu, Y., Zhang, X., Ning, J., & Zhang, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2169531 · Cited by 28
Expert opinions on immunotherapy for patients with colorectal cancer
Wang, F., Wang, Z., Chen, G., Luo, H., Zhang, D., Qiu, M., Wang, D., Pan, Z., Shen, L., Li, J., et al. (2020) · 癌症：英文版 · doi:10.1002/cac2.12095 · Cited by 27
Pan-cancer whole genome analyses of metastatic solid tumorsPreprint
Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/415133 · Cited by 27
Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28
Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients
Wei, W., & Luo, Z. (2017) · Medicine · doi:10.1097/md.0000000000008931 · Cited by 26
Lantuéjoul, S., Adam, J., Girard, N., Duruisseaux, M., Mansuet‐Lupo, A., Cazes, A., Rouquette, I., Gibault, L., Garcia, S., Antoine, M., et al. (2018) · Annales de Pathologie · doi:10.1016/j.annpat.2018.01.007 · Cited by 26
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
Wang, S., Hao, J., Wang, H., Fang, Y., & Tan, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457600 · Cited by 26
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma
Zarić, B., Brčić, L., Buder, A., Brandstetter, A., Buresch, J., Traint, S., Kovačević, T., Stojšić, V., Perin, B., Pirker, R., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.014 · Cited by 26
Tian, H., Kang, Y., Song, X., Xu, Y., Chen, H., Gong, X., Zhang, W., Xu, Y., Xia, X., Gao, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.024 · Cited by 26
Jia, M., Yao, L., Yang, Q., & Chi, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00168 · Cited by 26
Corrao, G., Marvaso, G., Ferrara, R., Russo, G. L., Gugliandolo, S. G., Piperno, G., Spaggiari, L., de Marinis, F., Orecchia, R., Garassino, M. C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.017 · Cited by 25
Kato, K., Doki, Y., Ura, T., Hamamoto, Y., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Kudo, T., Iwasa, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14380 · Cited by 26
Long, L., Chen, M., Yuan, Y. J., Ming, A. L., Guo, W., Wu, K., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.42610 · Cited by 27
Chan, S. L., Yip, T. C., Wong, V. W., Tse, Y., Yuen, B. W., Luk, H. W., Lui, R. N.-S., Chan, H. L., Mok, T. S. K., & Wong, G. L. (2020) · Cancer Medicine · doi:10.1002/cam4.3378 · Cited by 26
Verschraegen, C. F., Jérusalem, G., McClay, E. F., Iannotti, N. O., Redfern, C. H., Bennouna, J., Chen, F. L., Kelly, K. L., Mehnert, J. M., Morris, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001064 · Cited by 26
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
Roth, M., & Das, S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851201 · Cited by 28
Song, C., Wu, Z.-Q., Wang, Q., Wang, Y., Guo, Z., Li, S., & Hu, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.634697 · Cited by 24
An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma
Zhang, H., Hu, J., Liu, A., Qu, H., Jiang, F., Wang, C., Mo, S., & Sun, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651575 · Cited by 26
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Gavrielatou, N., Liu, Y., Vathiotis, I. A., Zugazagoitia, J., Aung, T. N., Shafi, S., Fernandez, A., Schalper, K., Psyrri, A. K., & Rimm, D. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2649 · Cited by 26
Tonse, R., Rubens, M., Appel, H. R., Tom, M. C., Hall, M. D., Odia, Y., McDermott, M. W., Ahluwalia, M. S., Mehta, M. P., & Kotecha, R. R. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab166 · Cited by 26
Wu, Y., Wu, H., Lin, M., Liu, T., & Li, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101268 · Cited by 26
Wang, L., Yang, Y., Yu, J., Zhang, S., Li, X., Wu, X., Nie, X., Liu, W., Zhang, P., Li, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14244 · Cited by 26
Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
Oitabén, A., Fonseca, P., Villanueva, M. J., García-Benito, C., López‐López, A., Fernández, A. G., González-Ojea, C., Juaneda‐Magdalena, L., Lázaro, M. E., & Martínez‐Fernández, M. (2022) · Cancers · doi:10.3390/cancers14112626 · Cited by 26
Wang, Y., Li, C., Wang, Z., Wang, Z., Wu, R., Wu, Y., Song, Y., & Liu, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02580-1 · Cited by 29
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
Dercle, L., Fronheiser, M. P., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.019 · Cited by 27
Immuno-Oncology—The New Paradigm of Lung Cancer Treatment
Dawe, D. E., Harlos, C. H., & Juergens, R. A. (2020) · Current Oncology · doi:10.3747/co.27.5183 · Cited by 26
Self-citationGlobal research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 27
Liang, S., Wang, H., Tian, H., Xu, Z., Wu, M., Hua, D., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249980 · Cited by 25
Kim, J., Cho, J., Lee, M. H., & Lim, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-30277-0 · Cited by 25
Hou, Y., Nitta, H., Parwani, A. V., & Li, Z. (2019) · Human Pathology · doi:10.1016/j.humpath.2018.12.007 · Cited by 25
Current Status of Immunotherapy for Lung Cancer and Future Perspectives
Kim, H. C., & Choi, C. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2019.0039 · Cited by 25
Chen, Y., Seeruttun, S. R., Wu, X.-Y., & Wang, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01432 · Cited by 25
Chiu, M., Lipka, M. B., Bhateja, P., Fu, P., & Dowlati, A. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.03 · Cited by 25
Lee, M.-H., Yanagawa, J., Tran, L. M., Walser, T. C., Bisht, B., Fung, E., Park, S. J., Zeng, G., Krysan, K., Wallace, W. D., et al. (2020) · PubMed Central · Cited by 25
Wang, Q., Yang, Y., Yang, M., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.103296 · Cited by 25
Wang, Y., Kong, D., Wang, C., Chen, J., Li, J., Liu, Z., Li, X., Wang, Z., Yao, G., & Wang, X. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820967454 · Cited by 25
Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis
Xie, Z., Li, X., Lun, Y., He, Y., Wu, S., Wang, S., Sun, J., He, Y., Xin, S., & Zhang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107090 · Cited by 25
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
Meriggi, F. A., & Zaniboni, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02786-3 · Cited by 26
Xu, Y., Wang, Q., Xie, J., Chen, M., Liu, H., Zhan, P., Lv, T., & Song, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732214 · Cited by 25
ICIs-Related Cardiotoxicity in Different Types of Cancer
Dong, M., Yu, T., Zhang, Z., Zhang, J., Wang, R., Tse, G., Liu, T., & Zhong, L. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070203 · Cited by 25
Cui, Y., Zhang, P., Liang, X., Xu, J., Liu, X., Wu, Y., Zhang, J., Wang, W. T., Zhang, F., & Guo, R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3991639 · Cited by 26
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma
Yin, N., Liu, Y., Weems, C. R., Shreeder, B., Lou, Y., Knutson, K. L., Murray, N. R., & Fields, A. P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq5931 · Cited by 25
Tomiyama, E., Fujita, K., Hashimoto, M., Adomi, S., Kawashima, A., Minami, T., Yoshimura, K., Uemura, H., & Nonomura, N. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-457 · Cited by 24
Liu, W., Huo, G., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10959-3 · Cited by 26
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
Tsiara, A., Liontos, M., Καπαρέλου, Μ., Zakopoulou, R., Bamias, A., & Dimopoulos, M. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.07 · Cited by 24
Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma
Díaz, L. R., Saavedra-López, E., Romarate, L., Mitxitorena, I., Casanova, P. V., Cribaro, G. P., Gallego, J. M., Pérez‐Vallés, A., Forteza‐Vila, J., Alfaro‐Cervelló, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120757 · Cited by 26
Abdel-Rahman, O. M., Oweira, H., & Giryes, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1528146 · Cited by 25
Qi, Z., Wang, L., Desai, K., Cogswell, J. P., Stern, M. A., Lawson, B., Kerkar, S. P., & Vitazka, P. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.04.011 · Cited by 25
Matsushita, H., Hasegawa, K., Oda, K., Yamamoto, S., Asada, K., Karasaki, T., Yabuno, A., Nishijima, A., Nejo, T., Kobayashi, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000375 · Cited by 24
Pang, Z., Chen, X., Wang, Y., Wang, Y., Yan, T., Wan, J., Wang, K., & Du, J. (2020) · Genomics · doi:10.1016/j.ygeno.2020.12.010 · Cited by 25
Sen, G., Öztaş, N. Ş., Değerli, E., Can, G., Turna, H., & Özgüroğlu, M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107347 · Cited by 24
Tu, X., Chen, L., Zheng, Y., Mu, C., Zhang, Z., Wang, F., Ren, Y., Duan, Y., Zhang, H., Tong, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02985-1 · Cited by 23
Crow, J., Samuel, G., & Godwin, A. K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1688144 · Cited by 24
Melosky, B. L., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Liu, G., & Cheema, P. K. (2020) · Current Oncology · doi:10.3747/co.27.6007 · Cited by 27
Self-citationRajurkar, S. P., Mambetsariev, I., Pharaon, R. R., Leach, B., Tan, T., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061870 · Cited by 25
Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers
Zhu, Y., Meng, X., Ruan, X., Lu, X., Yan, F., & Wang, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00702 · Cited by 26
Chae, Y. K., Kim, W. B., Davis, A. A., Park, L. C., Anker, J. F., Simon, N. I., Rhee, K., Song, J., Cho, A., Chang, S., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-148 · Cited by 24
Bishay, K., Tandon, P., Bourassa‐Blanchette, S., Laurie, S. A., & McCurdy, J. D. (2020) · Current Oncology · doi:10.3747/co.27.6251 · Cited by 26
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24
Peng, L., Yang, L., Gu, H.-T., Xiang, L., Xiong, Y., Wang, R., Zhou, H., & Wang, J. (2021) · Aging · doi:10.18632/aging.202756 · Cited by 24
Han, J., Yu, R., Duan, J., Li, J., Zhao, W., Feng, G., Bai, H., Wang, Y., Zhang, X., Wan, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6971 · Cited by 24
Self-citationSheng, L., Gao, J., Xu, Q., Zhang, X., Huang, M., Dai, X., Li, S., & Liu, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018537 · Cited by 24
Yoh, K., Matsumoto, S., Furuya, N., Nishino, K., Miyamoto, S., Oizumi, S., Okamoto, N., Itani, H., Kuyama, S., Nakamura, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.015 · Cited by 24
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Yan, Y., Cui, J., Fu, J., Su, Y.-J., Chen, X., Gu, Z., & Lin, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760737 · Cited by 24
Xiang, Z., Li, J., Zhang, Z., Cen, C., Chen, W., Jiang, B., Meng, Y., Wang, Y., Berglund, B., Zhai, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883655 · Cited by 23
Cuppens, K., Baas, P., Geerdens, E., Cruys, B., Froyen, G., Decoster, L., Thomeer, M., & Maes, B. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.019 · Cited by 24
Inoue, H., Shiozaki, A., Fujiwara, H., Konishi, H., Kiuchi, J., Ohashi, T., Shimizu, H., Arita, T., Yamamoto, Y., Morimura, R., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13377 · Cited by 24
Wang, W., Lin, G., Hao, Y., Guan, Y., Zhang, Y., Xu, C., Wang, Q., Wang, D., Jiang, Z., Cai, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.059 · Cited by 24
Clinical and technical insights of tumour mutational burden in non-small cell lung cancer
Meri-Abad, M., Moreno‐Manuel, A., Gallach, S., Fariñas, S. C., Sirera, R., Herrero, C. C., & Lewintre, E. J. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103891 · Cited by 25
Metadata
- Authors
- Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T. J. N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R., Villaruz, L. C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W. J., Bhagavatheeswaran, P., Chen, A. C., & Socinski, M. A.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Carbone, David P.
- Reck, Martin
- Paz-Ares, Luis
- Horn, Leora
- Felip, Enriqueta
- Ciuleanu, Tudor-Eliade
- Badin, Firas
- Ready, Neal
- Hiltermann, T. Jeroen N.
- Nair, Suresh
- Juergens, Rosalyn
- Peters, Solange
- Wrangle, John M.
- Borghaei, Hossein
- Blumenschein, George R.
- Villaruz, Liza C.
- Havel, Libor
- Chang, Han
- Geese, William J.
- Socinski, Mark A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-22
- Volume
- 376
- Issue
- 25
- Pages
- 2415-2426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6487310
- OpenAlex
- W2635951006
- Cited by
- 2,503
- References
- 20
- Citations by year
- 2026: 54 · 2025: 121 · 2024: 196 · 2023: 223 · 2022: 328 · 2021: 380 · 2020: 432 · 2019: 372 · 2018: 334 · 2017: 61
- FWCI
- 144.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (UG1CA233259, K12CA157688, P30CA016672, P30CA016058)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, non-small cell lung cancer, PD-L1 expression, first-line therapy, stage IV NSCLC, recurrent NSCLC, platinum-based chemotherapy, docetaxel, progression-free survival, overall survival, immune checkpoint inhibitors, treatment-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, PD-1/PD-L1 blockade
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Disease-Free Survival, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
